Peng Xiaodong, Li Yukun, Wang Xuesi, Ruan Yanfei, Liu Nian
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
National Clinical Research Center for Cardiovascular Diseases, Beijing, China.
Front Cardiovasc Med. 2022 Apr 12;9:739113. doi: 10.3389/fcvm.2022.739113. eCollection 2022.
The impact of elevated resting heart rate on early-stage renal dysfunction, manifesting as microalbuminuria, in hypertension is unclear. This study aimed to analyze the association between resting heart rate and microalbuminuria in patients with hypertension according to their blood pressure status. In addition, the effect of antihypertensive agents on this relationship was evaluated.
We searched the National Health and Nutrition Examination Survey for eligible participants from 2009 to 2018. Data on key parameters such as age, sex, blood pressure, heart rate, albumin creatinine ratio, and medication were collected for analysis. Subsequently, participants were classified according to the heart rate quartile and blood pressure status for subgroups assessment. A total of 5,692 participants were enrolled in this study. After adjusting the confounding factors, there was a linear association between resting heart rate and microalbuminuria in patients with hypertension (OR 1.184 [per 1 SD]; 95% CI: 1.101, 1.274; < 0.001). However, the association between elevated resting heart rate and microalbuminuria was not significant in patients with uncontrolled hypertension (OR 1.092 [per 1 SD]; 95% CI: 0.935, 1.275; = 0.269). The OR of the indirect effect of β-blockers on the risk of microalbuminuria incidence through heart rate was 0.926 (95% CI: 0.895, 0.956), while the direct effect was 1.374 (95% CI: 1.138, 1.662, = 0.010). Similarly, dihydropyridine calcium channel blockers were associated with a higher prevalence of microalbuminuria (OR 1.300, 95% CI: 1.058, 1.597, = 0.013), but the association between non-dihydropyridine calcium channel blockers and microalbuminuria was not significant (OR 1.207, 95% CI: 0.737, 1.978, = 0.454).
Elevated resting heart rate is associated with a high risk of microalbuminuria in untreated patients and patients with controlled hypertension. Although there is a linear association between heart rate and microalbuminuria, the use of β-blockers exhibits a significantly increase in the prevalence of microalbuminuria in hypertension. Likewise, dihydropyridine calcium channel blockers may increase the risk of microalbuminuria in hypertension.
静息心率升高对高血压患者早期肾功能不全(表现为微量白蛋白尿)的影响尚不清楚。本研究旨在根据血压状态分析高血压患者静息心率与微量白蛋白尿之间的关联。此外,还评估了抗高血压药物对这种关系的影响。
我们在2009年至2018年的美国国家健康与营养检查调查中搜索符合条件的参与者。收集年龄、性别、血压、心率、白蛋白肌酐比值和用药等关键参数的数据进行分析。随后,根据心率四分位数和血压状态对参与者进行分类以进行亚组评估。本研究共纳入5692名参与者。在调整混杂因素后,高血压患者的静息心率与微量白蛋白尿之间存在线性关联(OR 1.184[每1个标准差];95%CI:1.101,1.274;P<0.0)。然而,在未控制高血压的患者中,静息心率升高与微量白蛋白尿之间的关联并不显著(OR 1.092[每1个标准差];95%CI:0.935,1.275;P=0.269)。β受体阻滞剂通过心率对微量白蛋白尿发生风险的间接效应OR为0.926(95%CI:0.895,0.956),而直接效应为1.374(95%CI:1.138,1.662,P=0.010)。同样,二氢吡啶类钙通道阻滞剂与微量白蛋白尿的较高患病率相关(OR 1.300,95%CI:1.058,1.597,P=0.013),但非二氢吡啶类钙通道阻滞剂与微量白蛋白尿之间的关联不显著(OR 1.207,95%CI:0.737,1.978,P=0.454)。
静息心率升高与未治疗患者和血压控制良好的高血压患者微量白蛋白尿的高风险相关。虽然心率与微量白蛋白尿之间存在线性关联,但使用β受体阻滞剂会使高血压患者微量白蛋白尿的患病率显著增加。同样,二氢吡啶类钙通道阻滞剂可能会增加高血压患者微量白蛋白尿的风险。